Frozen Blood
Closed Pre-Solicitation Posted
- Solicitation number
- 12263311
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 339112 Surgical and Medical Instrument Manufacturing
- Place of performance
- Camp Lejeune, North Carolina 28547, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency Contracting Activity (DHACA) Healthcare Contracting Division-Southeast intends to procure CPDA triple blood bags and Glycerolyte 57% Solution configured and validated for use with specific medical equipment currently owned by the Naval Medical Center Camp Lejeune (NMCCL) Blood Donor Center in North Carolina. The procurement will be conducted on a sole source basis under FAR 13.501(a) with Fenwal, Inc., a Fresenius Kabi Company, as the proposed source. Key requirements include FDA approval for patient care, configuration and validation for the Haemonetic ACP 215s and AMICUS Separator Collection System, timely delivery, and compliance with federal and industry standards for product defects. Interested parties must submit technical data demonstrating capability to provide equivalent products; however, the Government will determine whether to proceed with competitive procurement at its sole discretion based on responses received. The deadline for submitting capability statements is November 18, 2025, and this notice of intent is not a request for formal competitive proposals, though responses will be evaluated for determining source capability.
This procurement carries no set-aside restrictions and represents a requirement for medical blood collection supplies classified under NAICS 339112 (Surgical and Medical Instrument Manufacturing) and PSC 6550 (In Vitro Diagnostic Substances, Reagents, Test Kits and Sets). The current potential incumbent is Fenwal, Inc., located at Three Corporate Drive, Lake Zurich, Illinois 60047. The contract delivery period spans from December 1, 2025, through September 30, 2026, providing a nine-month supply window for the Naval Medical Center. No specific budget range or quantity of goods has been disclosed in this pre-solicitation notice. Vendors challenging the requirement basis or seeking additional information should contact the contracting office via the provided email address. The Government's decision not to compete based on capability statements submitted in response to this notice remains entirely discretionary.
Notice text
The Defense Health Agency Contracting Activity (DHACA) Healthcare Contracting Division- Southeast (HCD-Southeast) intends to negotiate on a sole source basis IAW FAR 13.501(a), Only One Responsible Source. The proposed source is Fenwal, Inc., a Fresenius Kabi Company (Fenwal) of Three Corporate Drive, Lake Zurich, IL 60047.
The Naval Medical Center Camp Lejeune (NMCCL), NC Blood Donor Center has a requirement for CPDA triple blood bags and Glycerolyte 57% Solution. The requested items shall be configured and validated for use with the Haemonetic ACP 215s that NMCCL currently owns. The items shall be Food and Drug Administration (FDA), which is approved for patient care. The requested supplies shall be configured and validated for use with the AMICUS™ Separator Collection System that NMCCL currently owns. The supplies shall be delivered timely, and products shall be free of defects in accordance with federal and industry standards per Food and Drug Administration (FDA) regulations. The supplies shall be provided for a delivery period from 01 December 2025 – 30 September 2026.
There are no set-aside restrictions for this requirement. The intended procurement will be classified under North America Industry Classification System (NAICS) 339112. This notice of intent is not a request for competitive proposals and no solicitation document exists for this requirement. However, parties interested in responding to this notice will need to submit technical data sufficient to determine capability in providing the same product. All capability statements received by the closing date of this synopsis will be considered by the Government. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.
If a vendor challenges the basis of this requirement, please email product capability statements (formats for submission: PDF, MS Word, or MS Excel) to Gerrie Johnson at Gerrie.m.johnson.civ@health.mil . Closing date for challenges is no later than 4:00 PM ET on 18 November 2025. No phone calls will be accepted.
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| PANDHA-26-P-0000 046638 Defibrinated Rabbit Blood | Defense Health Agency | No set-aside | |
| 6505--Human Blood and Blood Products | Veterans Integrated Service Network 17 | No set-aside | |
| Q301--VA Boise, Idaho - Blood Bank Reagents Requirement | Veterans Integrated Service Network 20 | No set-aside | |
| Operational Medicine Test and Evaluation Cell Salvage Supplemental - (AFMEDCOM) | Air Force Installation Contracting Agency | No set-aside | |
| 6550--hemochron signature elite reagents and supplies | Veterans Integrated Service Network 22 | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity